The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.

Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.

Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.

The disclosure provides antibodies, antibody fragments, and antibody derivatives that bind to the viral envelope spike protein (S2P) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and related compositions, and methods. In some embodiments, the antibodies, antibody fragments, and antibody derivatives bind to an epitope of the receptor binding domain (RBD) of SARS-CoV-2.

The disclosure provides antibodies, antibody fragments, and antibody derivatives that bind to the viral envelope spike protein (S2P) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and related compositions, and methods. In some embodiments, the antibodies, antibody fragments, and antibody derivatives bind to an epitope of the receptor binding domain (RBD) of SARS-CoV-2.

Disclosed herein are antibodies to SARS-CoV-2 antigens and recombinant nucleic acid sequences that encode the SARS-CoV-2 antibodies. The disclosure also provides a method of preventing and/or treating a SARS-CoV-2 infection or disease or disorder associated with SARS-CoV-2 infection (e.g., COVID-19) in a subject using said compositions and methods.

Disclosed herein are antibodies to SARS-CoV-2 antigens and recombinant nucleic acid sequences that encode the SARS-CoV-2 antibodies. The disclosure also provides a method of preventing and/or treating a SARS-CoV-2 infection or disease or disorder associated with SARS-CoV-2 infection (e.g., COVID-19) in a subject using said compositions and methods.

The present invention relates to immunogenic immune complexes, related compositions, and related methods.

The present invention relates to immunogenic immune complexes, related compositions, and related methods.